Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Genomics, Degussa Partner on Arthritis Nutraceuticals

NEW YORK, April 7 - Galapagos Genomics, a functional genomics company based in Belgium, said today that it is collaborating with Degussa BioActives to identify nutraceuticals with beneficial effects in the field of arthritis.


Galapagos will design human cellular assays based on its functional genomics platform, and will screen libraries of natural compounds to identify leads. Degussa has exclusive rights to commercialize any nutraceuticals that result from the collaboration, while Galapagos is eligible for milestone payments and royalties on the commercialization of these products.


Onno van de Stolpe, CEO of Galapagos, said the partnership is the company's first foray into the nutraceutical field, and "has the potential to become an important income generator for Galapagos."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.